The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

British Journal of Cancer

Volumn 104, Issue 2, 2011, Pages 241-247

  Shinohara, N ^a   Takahashi, M ^b   Kamishima, T ^a   Ikushima, H ^b   Otsuka, N ^a   Ishizu, A ^c   Shimizu, C ^d   Kanayama, H ^b   Nonomura, K ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

hypothyroidism; renal cell carcinoma; sunitinib; thyroid atrophy

Indexed keywords

LEVOTHYROXINE; LEVOTHYROXINE SODIUM; SUNITINIB; THYROTROPIN;

ADULT; AGED; ARTICLE; ATROPHY; AUTOPSY; BLOOD VESSEL; CELL DEGENERATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; KIDNEY CARCINOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THYROID ATROPHY; THYROID DISEASE; THYROID FOLLICLE; THYROID FOLLICLE CELL; THYROID FUNCTION; THYROID WEIGHT; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PYRROLES; THYROID FUNCTION TESTS; THYROID GLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78751579135     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606029     Document Type: Article

References (19)

1. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypo-thyroidism after sunitinib treatment for patients with gastrointestinal stromal tumor. Ann Intern Med 145: 660-664
2. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576
3. Kato F, Kamishima T, Morita K, Muto NS, Okamoto S, Omatsu T, Oyama N, Terae S, Kanegae K, Nonomura K, Shirato H (2009) Rapid estimation of split renal function in kidney donors using software developed for computed tomographic renal volumetry. Eur J Radiol, e-pub ahead of print 4 December 2009; doi:10.1016/j.ejrad.2009.11.013
4. Langer P (1989) Normal thyroid size versus goiter-postmortem thyroid weight and ultrasonographic volumetry versus physical examination. Endocrinol Exp 23: 67-76
5. Lee DH, Cho KJ, Sun DI, Hwang SJ, Kim DK, Kim MS, Cho SH (2006) Thyroid dimensions of Korean adults on routine neck computed tomography and its relationship to age, sex, and body size. Surg Radiol Anat 28: 25-32
6. Makita N, Miyakawa M, Fijita T, Iiri T (2010) Sunitinib induces hypo-thyroidism with a markedly reduced vascularity. Thyroid 20: 323-326
7. Mannavola D, Coca P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92: 3531-3534
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal-cell carcinoma. J Clin Oncol 27: 3584-3590
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
10. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
11. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006b) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524 (Pubitemid 43854967)
12. Nygaard B, Nygaard T, Court-Payen M, Jensen LI, Søe-Jensen P, Gerhard Nielsen K, Fugl M, Hegedüs L (2002) Thyroid volume measured by ultrasonography and CT. Acta Radiol 43: 269-274
13. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81-83
14. Rogiers A, Wolter P, de Beeck KO, Thijs M, Decallonne B, Schoffski P (2010) Shrinkage of thyroid volume in sunitinib-treated patients with renal cell carcinoma: a potential marker of irreversible thyroid dysfunction. Thyroid 20: 317-322
15. Salem AK, Fenton MS, Marion KM, Hershman JM (2008) Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18: 631-635
16. Theou-Anton N, Faivre S, Dreyer C, Raymond E (2009) Benefit-risk assessment of sunitinib in gastrointestinal stromal tumors and renal cancer. Drug Saf 32: 717-734
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216 (Pubitemid 30099779)
18. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H (2010) A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. Jpn J Clin Oncol 40: 194-202
19. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99: 448-454